Showing results (61-70 of 70) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2022
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA TrialTheodore W Laetsch, Shannon L Maude, Susana Rives, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2021
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium ReportLiora M Schultz, Christina Baggott, Snehit Prabhu, et al.Haematologica|December 28, 2023
LNK/SH2B3 as a novel driver in juvenile myelomonocytic leukemiaAstrid Wintering, Anna Hecht, Julia Meyer, et al.NEJM Evidence|May 22, 2024
CAR T-Cell Immunotherapy in Minority Patients with LymphomaGuido Ghilardi, Staci Williamson, Raymone Pajarillo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2026
Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALLStephan A Grupp, Shannon L Maude, Susana Rives, et al.The Lancet. Oncology|April 3, 2025
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysisAndrew D J Pearson, Claudia Rossig, Crystal L Mackall, et al.Blood Advances|July 21, 2025
Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecelSwati Naik, Subodh Selukar, Aimee C Talleur, et al.Frontiers in Immunology|November 15, 2023
Mediport use as an acceptable standard for CAR T cell infusionMaya Eylon, Snehit Prabhu, Samuel John, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 4, 2019
Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell TransplantationBetty K Hamilton, Ying Liu, Michael T Hemmer, et al.Transplantation and Cellular Therapy|July 26, 2021
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular TherapyMohamed A Kharfan-Dabaja, Ambuj Kumar, Ernesto Ayala, et al.Pageof 7